VA-REGULA
15.2.2024 08:01:33 CET | Business Wire | Press release
Frost & Sullivan recognizes companies with Best Practices Awards in various categories for outstanding efforts to inspire growth in their industries. Businesses that earn these awards identify emerging trends before they become the market standard and create solutions that drive differentiation and sustainable growth. Frost & Sullivan considers these companies to be the game changers.
As for the Enabling Technology Leadership Award in the identity verification (IDV) industry, Frost & Sullivan applies a rigorous analytical process to assess multiple nominees. This involves a detailed evaluation of best practices criteria across two dimensions: Technology Leverage and Customer Impact. Frost & Sullivan points out that Regula excels in many of the criteria in the IDV solutions space.
Synergizing cutting-edge verification technologies with an intuitive user-centric design. Experts emphasize Regula's product portfolio, seamlessly integrating a single-vendor solution for complete identity verification based on biometric (Regula Face SDK) and document (Regula Document Reader SDK) checks with enhanced authenticity validation, along with forensic devices dedicated to in-depth examination. At the heart of Regula’s IDV solution lies the most comprehensive database encompassing over 13,500 documents from 247 countries and territories, supporting over 138 languages.
Regula distinguishes itself by fostering innovation through in-house development of all technologies, steering clear of third-party dependencies. Notably, its standout feature is the platform-agnostic nature of its digital identification solutions. This enables customers to orchestrate an enhanced ID verification process effortlessly on any platform—be it mobile, web, desktop platforms, or passport readers.
Forging strategic alliances with renowned international organizations. Regula forges strategic partnerships with esteemed organizations like the International Air Transport Association, International Organization for Migration, and International Civil Aviation Organization. This collaborative effort establishes Regula as an integral player in a symbiotic exchange of insights and vital information about documents. This ongoing collaboration serves as a catalyst for continuously refining its technologies, positioning the company at the forefront of innovation.
Transforming customer workflows in many industries through value-driven verification solutions. Regula's distinctive offering lies in its rich heritage in the forensics space. The one-stop-shop nature of Regula’s solutions eradicates the necessity for customers to enlist multiple vendors for additional security measures and ensures a comprehensive strategy addressing security, forensics, and identity verification requirements in a seamless and integrated manner.
Enduring excellence through long-term customer relationships. Regula’s value-driven identity verification solutions extend across a spectrum of industry verticals, including banking, fintech, aviation, telecommunication, government authorities, healthcare, insurance, forensic labs, gambling, and others. The company's achievements are evidenced by providing hardware and software solutions for digital identity verification to a global network of over 1,000 organizations and 80 border control authorities. Notably, Regula's clientele includes major players such as the largest private bank globally, and prominent airline companies like AirAsia and WizzAir. Also, Regula has solidified its position as a trusted technology partner for several years at the Mobile World Congress (MWC), a premier international industry event organized by the GSMA.
On top of this, Frost & Sullivan believes Regula outperforms in responding to the complex landscape of identity fraud. Rabin Dhakal, Frost & Sullivan Best Practices Research Analyst states: “In the face of an escalating wave of sophisticated fraud, identity theft, and scams, the urgency for a robust identity verification solution has never been more pronounced. Frost & Sullivan believes that Regula’s proactive response to the evolving landscape of document fraud and fakes is unprecedented.”
"We are truly honored to be acknowledged by a prominent expert in market growth and innovations. We strive to emphasize the key differentiator for Regula, which lies in the wealth of experience gained over three decades - specifically in understanding documents and verification processes, our comprehensive document template database, full-cycle in-house production, and the team of top-notch forensic experts. These are the assets that enable us to drive continuous innovation and provide a comprehensive solution to identity verification,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about the 2024 Frost & Sullivan Global Enabling Technology Leadership Award in the identity verification solutions industry, please read the report.
About Frost & Sullivan
Frost & Sullivan is the Growth Pipeline Company™. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service™ provides the CEO and the CEO's growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214825831/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom